Orphanet Journal of Rare Diseases | Clinical and Economic Burden Analysis of Achondroplasia Subtype

Recommend:

This study is the first systematic assessment of the clinical and economic burden of patients with Achondroplasia in real-world clinical practice in the United States, revealing a significant impact on patients' health and healthcare resource utilization, especially in the subgroup with comorbid spinal stenosis (Ach-SpS). The findings provide real-world evidence support for the development of disease-modifying therapies.

 

Literature Overview
This article, titled 'Clinical burden and healthcare resource utilization associated with achondroplasia: a real-world observational, retrospective cohort study', published in the Orphanet Journal of Rare Diseases, reviews and summarizes the significant clinical and healthcare resource utilization burden associated with achondroplasia, particularly showing higher hospitalization rates and total healthcare costs in both pediatric and adult populations. The study further analyzes the healthcare burden in the achondroplasia with spinal stenosis (Ach-SpS) subgroup.

Background
Achondroplasia is a rare inherited skeletal dysplasia caused by mutations in the FGFR3 gene, with a global prevalence of approximately 250,000 individuals. It is the most common form of disproportionate short stature and is associated with increased early mortality and reduced life expectancy. Although drugs like vosoritide have been approved, patients still require frequent multidisciplinary clinical management and surgical interventions. Achondroplasia is often accompanied by complications such as spinal stenosis, leg deformities, ENT disorders, and sleep disturbances, which significantly affect patients' quality of life and increase healthcare expenditures. This study fills the gap in real-world data from the United States regarding the clinical and economic burden of achondroplasia, especially highlighting the high healthcare resource use and costs in the Ach-SpS subgroup. Future research should explore the potential impact of disease-modifying therapies and metabolic syndrome to improve patient outcomes.

 

A tool to assess the pathogenicity of genetic variants, providing reference for functional analysis.

Learn More

 

Research Methods and Design
This study employed a retrospective cohort design using the Optum de-identified Clinformatics® Data Warehouse (CDM) database to identify patients diagnosed with achondroplasia between October 1, 2015, and October 1, 2023. The study cohort included 626 achondroplasia patients, matched 1:5 with 3,130 controls based on age, sex, index date, and follow-up duration. Patient data were stratified by age (<18 and ≥18 years) and analyzed for the subgroup with comorbid spinal stenosis (Ach-SpS). Key outcomes included comorbidities, healthcare resource utilization (HCRU), and total healthcare costs per person-year (PPY). Statistical analyses included t-tests, chi-square tests, generalized linear models, and two-part models to compare differences between groups.

Key Findings and Insights

• Achondroplasia patients demonstrated significantly higher rates of comorbidities in both pediatric and adult populations, including skeletal and non-skeletal conditions such as spinal stenosis, pain, sleep apnea, anxiety, and depression.
• Healthcare resource utilization was significantly increased among achondroplasia patients compared to controls, with an average of 0.30 hospitalizations per year in the pediatric group and 0.39 in the adult group, both significantly higher than controls.
• Total annual healthcare costs were also significantly elevated in achondroplasia patients: $31,388 for children and $33,360 for adults, primarily driven by inpatient and outpatient expenses.
• The Ach-SpS subgroup showed even higher HCRU and total costs, with an average annual total cost of $45,990 and inpatient costs of $25,399, both exceeding the overall achondroplasia cohort.
• The study also found significantly increased non-skeletal complications in adult achondroplasia patients, such as obesity, hypertension, arthritis, and anxiety, highlighting the need for multisystem management.

Implications and Future Directions
This study provides the first systematic assessment of the clinical and economic burden of achondroplasia in the United States, emphasizing its impact across multiple life stages. The findings support the development of more effective disease-modifying therapies and provide a data foundation for multidisciplinary management. Future research should evaluate the potential role of metabolic syndrome, mental health issues, and AAV gene therapy strategies in achondroplasia. Additionally, multinational studies are needed to validate the generalizability of these findings.

 

A tool to retrieve reference sequences, transcripts, and exon information for specific genes, accelerating gene research.

Learn More

 

Conclusion
By analyzing real-world U.S. data, this study reveals that achondroplasia patients face significant clinical and economic burdens during both childhood and adulthood, with even higher healthcare resource utilization and costs observed in the subgroup with spinal stenosis. The study highlights unmet medical needs in the current disease management paradigm and provides important insights for future therapeutic development and clinical optimization. These findings enhance understanding of the multisystem impact of achondroplasia and support the implementation of more targeted interventions.

 

Pranav Abraham, Gandarvaka Miles, Natalia Petruski-Ivleva, Cemre Robinson, and Kenneth I Berger. Clinical burden and healthcare resource utilization associated with achondroplasia: a real-world observational, retrospective cohort study. Orphanet Journal of Rare Diseases.